Related Experiment Video
Updated: Jun 22, 2025
Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
Published on: September 21, 2017
Therapeutic Nonsense Suppression Modalities: From Small Molecules to Nucleic Acid-Based Approaches
Pedro Morais1, Rui Zhang2, Yi-Tao Yu2
1Drug Metabolism and Pharmacokinetics, Research and Development, Bayer Pharmaceuticals, 42113 Wuppertal, Germany.
Abstract:
Nonsense mutations are genetic mutations that create premature termination codons (PTCs), leading to truncated, defective proteins in diseases such as cystic fibrosis, neurofibromatosis type 1, Dravet syndrome, Hurler syndrome, Beta thalassemia, inherited bone marrow failure syndromes, Duchenne muscular dystrophy, and even cancer. These mutations can also trigger a cellular surveillance mechanism known as nonsense-mediated mRNA decay (NMD) that degrades the PTC-containing mRNA. The activation of NMD can attenuate the consequences of truncated, defective, and potentially toxic proteins in the cell. Since approximately 20% of all single-point mutations are disease-causing nonsense mutations, it is not surprising that this field has received significant attention, resulting in a remarkable advancement in recent years. In fact, since our last review on this topic, new examples of nonsense suppression approaches have been reported, namely new ways of promoting the translational readthrough of PTCs or inhibiting the NMD pathway. With this review, we update the state-of-the-art technologies in nonsense suppression, focusing on novel modalities with therapeutic potential, such as small molecules (readthrough agents, NMD inhibitors, and molecular glue degraders); antisense oligonucleotides; tRNA suppressors; ADAR-mediated RNA editing; targeted pseudouridylation; and gene/base editing. While these various modalities have significantly advanced in their development stage since our last review, each has advantages (e.g., ease of delivery and specificity) and disadvantages (manufacturing complexity and off-target effect potential), which we discuss here.
Insights
Nonsense mutations cause genetic diseases by creating faulty proteins. New therapies aim to correct these mutations by promoting protein production or blocking cellular degradation pathways.
Area of Science:
- Genetics
- Molecular Biology
- Biochemistry
Background:
- Nonsense mutations introduce premature termination codons (PTCs), yielding truncated, non-functional proteins.
- These mutations are implicated in numerous genetic disorders, including cystic fibrosis, Duchenne muscular dystrophy, and various cancers.
- Nonsense-mediated mRNA decay (NMD) is a cellular mechanism that degrades PTC-containing mRNA, potentially limiting disease severity.
Purpose of the Study:
- To provide an updated review of state-of-the-art nonsense suppression technologies.
- To focus on novel therapeutic modalities for treating diseases caused by nonsense mutations.
- To discuss the advantages and disadvantages of various emerging treatment strategies.
Main Methods:
- Review of recent advancements in nonsense suppression strategies.
- Analysis of therapeutic modalities including small molecules, antisense oligonucleotides, tRNA suppressors, ADAR-mediated RNA editing, targeted pseudouridylation, and gene/base editing.
- Discussion of the mechanisms, potential, and challenges associated with each modality.
Main Results:
- Significant progress has been made in developing new approaches for nonsense suppression.
- Novel strategies include promoting translational readthrough of PTCs and inhibiting the NMD pathway.
- Emerging modalities show therapeutic potential but also present challenges in manufacturing and off-target effects.
Conclusions:
- Nonsense suppression technologies are rapidly advancing, offering new therapeutic avenues for genetic diseases.
- Each modality, from small molecules to gene editing, has unique benefits and drawbacks.
- Continued research is crucial to overcome limitations and translate these promising technologies into effective clinical treatments.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:27Nonsense-mediated mRNA Decay
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:20Types of RNA
RNA Performs Diverse...
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...